Literature DB >> 940955

Disposition kinetics of dihydroquinidine following quinidine administration.

C T Ueda, B J Williamson, B S Dzindzio.   

Abstract

The disposition kinetics of dihydroquinidine, a known impurity in drug grade quinidine, was studied in 7 patients who were hospitalized for control of cardiac arrhythmias. Quinidine gluconate injection containing 5.4 to 6.2 percent dihydroquinidine was used. Following an overnite fast, dihydroquinidine doses of 0.16 to 0.31 mg/kg base were infused intravenously over 22 min. Plasma samples were collected at various times for 12 hr and analyzed for dihydroquinidine by a thin layer chromatography-fluorometric assay procedure. Postinfusion plasma dihydroquinidine concentration decline was described by a biexponential equation which suggested that the impurity distributes within the body in two kinetically distinguishable pools. The volume of the central pool (Vc) and steady-state volume of distribution (Vdss) were 0.67 +/- 0.15 L/kg and 2.76 +/- 0.63 L/kg, respectively. The halflife of the fast (t1/2alpha) and slow (t1/2beta) disposition processes were 4.71 +/- 0.26 min and 5.71 +/- 1.00 hr. Total plasma clearance was 4.17 +/- 0.68 ml/min/kg. Renal excretion of intact dihydroquinidine accounted for 16 percent of the administered dose. The corresponding value for renal dihydroquinidine clearance (Clr) was 0.61 +/- 0.08 ml/min/kg. The results of this study indicated that there were no significant differences in the distribution and elimination characteristics of dihydroquinidine and quinidine.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 940955

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  7 in total

1.  Pharmacokinetics of quinidine related to plasma protein binding in man.

Authors:  D Fremstad; O G Nilsen; L Storstein; J Amlie; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

Review 2.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

3.  Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.

Authors:  C T Ueda; B S Dzindzio
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

5.  Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.

Authors:  P Jaillon; J M Poirier; B Lecocq; C Jarreau; M Pays; M O Richard; G Cheymol
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jul-Sep       Impact factor: 2.441

6.  Absorption of quinidine and dihydroquinidine in humans.

Authors:  D M Hailey; A R Lea; D M Coles; P E Heaume; W J Smith
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration.

Authors:  M Chimienti; M B Regazzi; M T La Rovere; J A Salerno; M Previtali; V Montericcio; R Rondanelli; C Montemartini
Journal:  Cardiovasc Drugs Ther       Date:  1988-12       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.